Absci vs CG Oncology
CG Oncology reported revenue of $4 million in fiscal 2025, 1.4 times Absci's $3 million in fiscal 2025. Absci's revenue fell 38.2% in its latest year, and CG Oncology's grew 254.7%. Absci had an operating margin of -4297.0%, against -4722.1% at CG Oncology. Free cash flow was −$94 million at Absci and −$132 million at CG Oncology.
Side by side
| Absci | CG Oncology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3M | $4M |
| Revenue growth | −38.2% | 254.7% |
| Revenue growth a year, last 5 years | −10.2% | — |
| Gross margin | — | — |
| Operating margin | −4,297.0% | −4,722.1% |
| Net margin | −4,113.7% | −3,985.0% |
| Free cash flow | −$94M | −$132M |
| Free cash flow margin | −3,358.3% | −3,279.2% |
| Return on capital | −162.8% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 24.1% | 23.7% |
| Last close | $8.45 | $74.40 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $933,174, sold $132,328 | bought $24.8 million, sold $4.8 million |
| Piotroski F-score | 3 of 8 | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbsciCG Oncology
Operating margin
Percent of revenue
AbsciCG Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbsciCG Oncology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Absci and CG Oncology pages.